Rasagiline Added to Aricept in Patients With Mild to Moderate Alzheimer's Disease

Study Title

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

Teva Identifier

TVP-1012-A001-201

ClinicalTrials.gov Identifier

NCT00104273

Study Status

Completed

Trial Condition(s)

Dementia | Alzheimer's Disease

Interventions

Drug: Rasagiline

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

45 Years to 90 Years

Trial Duration

08/01/2004 - 01/00/1900

Phase

Phase 2

Study Type

Interventional